Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab High Dose in Heavy Weight Psoriasis
NCT03504852Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Jun 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03504852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504852.